Stockscreener 앱 받기
34.17
1.57%
-0.545
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Third-quarter results are due at 7 a.m. Oct. 29 from Indivior. - Stock Titan
With 77.27% of shares represented, Indivior (INDV) stockholders vote on merger-related share issuance. - Stock Titan
A $1B special dividend features in Indivior (INDV)'s revised merger valuation details. - Stock Titan
Indivior stock pre-market at EUR 32.10: plus 0.00 percent - AD HOC NEWS
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire
Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media
Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart
An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan
Indivior declares $8.13 special dividend contingent on merger - Investing.com India
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing - Quiver Quantitative
Indivior declares $8.13 special dividend contingent on merger - Investing.com
Indivior Pharmaceuticals, Inc. SEC Filing (Sep 14, 2026) - Stock Titan
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS
Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Price to earnings forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indiv - The National Law Review
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Indivior stock trades below fair value as latest earnings beat expectations - AD HOC NEWS
Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight - sahmcapital.com
Indivior Pharmaceuticals CAO Woodrow D. Anderson Acquires 1,500 Shares at $35.69 Each - Kalkine Media
Indivior (INDV) accounting chief adds 1,500 shares in market or private buy - Stock Titan
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - theglobeandmail.com
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior Q2 2026 Earnings Call: Complete Transcript - Benzinga
Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - webull.com
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
2.96%
0.53%
자본화:
|
볼륨(24시간):